Abiopharma

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

American Business Bank Ranked 6th in Top 50 Community Banks With Assets Between $3 Billion and $10 Billion for 2025

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

MetLife and Highlights Launch Free Soccer-Themed Digital Magazine to Help Boost Kid’s Confidence

VYNE Therapeutics Updates for 06/02/2026

BitGo and Concrete Partner to Launch Institutional Onchain Optimized Asset Growth Platform

Snowflake Advances Trusted AI with Snowflake Horizon Catalog Centralizing Governance, Context, and Security Across the Enterprise

Clinical trial NCT03967743 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2025-12-01 → 2026-05-01 3. primary completion date: 2025-06-01 → 2024-03-11 4. enrollment: 150 → 43 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07462611 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-03-30 → 2026-04-08

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine